Click the logo below to access information on our medicines
PBS Information: Authority required for the use of Revlimid in multiple myeloma. Please refer to PBS schedule for full Authority information.
Before prescribing Revlimid® (lenalidomide) please refer to the full Product Information which is available here.
Do not use Revlimid during pregnancy. Teratogenic Effects: Revlimid (lenalidomide) is structurally related to thalidomide. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is taken during pregnancy, it may cause birth defects or death to an unborn baby. Women should be advised to avoid pregnancy whilst taking Revlimid (lenalidomide), during dose interruptions, and for 4 weeks after stopping the medication.
PBS Information: Authority required for the use of Pomalyst in multiple myeloma. Please refer to PBS schedule for full Authority information.
Before prescribing Pomalyst® (pomalidomide) please refer to the full Product Information which is available here
Refer to PI documents for dexamethasone and bortezomib.
Do not use Pomalyst during pregnancy. Teratogenic Effects: Pomalyst (pomalidomide) is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If pomalidomide is taken during pregnancy, it may cause birth defects or death to an unborn baby. Women should be advised to avoid pregnancy whilst taking Pomalyst (pomalidomide), during dose interruptions, and for 4 weeks after stopping the medicine.
PBS Information: Authority required for the use of Empliciti in multiple myeloma. Please refer to PBS schedule for full Authority information.
Before prescribing Empliciti® (elotuzumab) please refer to the full Product Information which is available here
Refer to PI documents for dexamethasone.
Abbreviations:
PBS: pharmaceutical benefits scheme.